Has Pascal Dauphin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $924,785 in general payments to Pascal Dauphin, MD across 2,200 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pascal Dauphin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pascal Dauphin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pascal Dauphin, MD

Endocrinology, Diabetes & Metabolism · Hendersonville, TNNPI 1154324325

Payments from drug & device makers

$924,785in general payments, 2019–2025

Across 2,200 payments — averaging $420.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$441K
Amgen$181K
AstraZeneca$74K
Radius Health, Inc.$40K
Merck$39K
Sanofi-aventis U.S. LLC$25K
plus $123K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	778	$441,150
Amgen(2 entities)	328	$180,856
AstraZeneca(2 entities)	158	$74,473
Radius Health, Inc.	57	$40,375
Merck	60	$39,108
Sanofi-aventis U.S. LLC	89	$25,445
Bayer	34	$22,000
Amarin Pharma, Inc.	64	$21,848
Xeris Pharmaceuticals, Inc.	74	$20,593
Esperion Therapeutics, Inc.	45	$18,623
Novo Nordisk	109	$14,025
Clarus Therapeutics Inc.	23	$12,079
Corcept Therapeutics	26	$3,045
Valeritas, Inc.	6	$2,002
Senseonics, Incorporated	3	$1,200
Insulet Corporation	32	$782
BETA Bionics, Inc.	18	$720
Boehringer Ingelheim	39	$711
Medtronic(2 entities)	28	$586
Mannkind Corporation	30	$561
Ascensia Diabetes Care US Inc.	8	$396
Averitas Pharma Inc.	12	$386
AbbVie	19	$349
Abbott	18	$331
Novartis	10	$294
Antares Pharma, Inc.	13	$234
Zealand Pharma US, Inc.	5	$232
Vistapharm, Inc.	12	$220
Cequr Corporation	3	$220
IBSA Pharma Inc.	10	$189
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	10	$180
Sequel Med Tech, LLC	6	$172
Ultragenyx Pharmaceutical Inc.	7	$155
Currax Pharmaceuticals LLC	10	$134
Dexcom, Inc.	4	$132
Ascendis Pharma Endocrinology Inc	6	$129
Tandem Diabetes Care, Inc.	7	$124
Endo Pharmaceuticals Inc.	5	$90
Amneal Pharmaceuticals LLC	4	$78
Madrigal Pharmaceuticals	2	$59
Tolmar, Inc.	3	$50
OPKO Pharmaceuticals, LLC	2	$43
Recordati_rare_diseases_inc.	2	$41
Nevro Corp.	2	$41
Companion Medical, Inc.	2	$38
Johnson & Johnson	2	$37
Pfizer	2	$34
Intra-sana Laboratories	2	$30
Shire North American Group Inc	2	$27
Halozyme Inc	1	$25
GSK	1	$23
Kyowa Kirin, Inc.	1	$21
Nalpropion Pharmaceuticals LLC	1	$20
Takeda Pharmaceuticals U.S.A., Inc.	1	$18
Eisai Inc.	1	$13
Aytu Biopharma, Inc.	1	$13
Amphastar Pharmaceuticals, Inc.	1	$13
Sun Pharmaceutical Industries Inc.	1	$12

How this compares

$924,785 in reported general payments places this provider in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee →

Medicare billing

Part B allowed, 2024

$129,687

Medicare patients

453

Services billed

3,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Hendersonville

Stephen SharpNashville$25.9M
Lisa UsdanMemphis$14.3M
Kathryn DahirNashville$11M
David HuffmanChattanooga$2.4M
Pedro VelasquezMemphis$2.4M
Craig WierumNashville$1.7M
Alan CohenMemphis$1.5M
Terri JerkinsNashville$1.2M
Aidar GosmanovMemphis$833K
Shichun BaoNashville$735K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →